SCHEMBL3563703

SCHEMBL3563703

COC(=O)c1ccccc1S(=O)(=O)Nc1ccc(OCCOc2ccccc2CC(=O)O)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
MMP2 P08253 3/20 0.45
MMP13 P45452 3/20 0.45
L3MBTL1 Q9Y468 2/20 0.44
MAPT P10636 2/20 0.44
FABP4 P15090 1/20 0.44
PTPN2 P17706 1/20 0.43
PTPN1 P18031 1/20 0.43
PTPN5 P54829 1/20 0.43
GAA P10253 2/20 0.43
NPC1 O15118 1/20 0.43
TDP1 Q9NUW8 1/20 0.42
POLB P06746 2/20 0.42
TSHR P16473 1/20 0.42
TNF P01375 1/20 0.42
NOD2 Q9HC29 1/20 0.42
NOD1 Q9Y239 1/20 0.42
FABP1 P07148 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4778244 0.90 MEN1 (0.53) MEN1KMT2AMMP2MMP13L3MBTL1
SCHEMBL3553852 0.83 L3MBTL1 (0.67) MEN1KMT2AL3MBTL1MAPTFABP4
SCHEMBL3563411 0.83 AR (0.54) MEN1KMT2AMAPTTDP1POLB
SCHEMBL3560475 0.82 HDAC1 (0.55) MEN1KMT2AMMP2MMP13MAPT
SCHEMBL3561911 0.82 SLC22A12 (0.44) MMP2MMP13L3MBTL1MAPTPTPN2
SCHEMBL3563514 0.82 SLC22A12 (0.50) MEN1KMT2AMMP2MMP13FABP1
SCHEMBL3556589 0.82 ALPL (0.47) MMP2MMP13FABP4POLBFABP1
SCHEMBL3553506 0.82 KMT2A (0.45) MEN1KMT2AL3MBTL1MAPTGAA
SCHEMBL3553434 0.81 MEN1 (0.42) MEN1KMT2AMMP2MMP13L3MBTL1
SCHEMBL3553907 0.81 AR (0.61) MEN1KMT2AMMP2MMP13L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US claimed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US claimed
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US disclosed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes SLC5A1, ALDH7A1, ASS1 MEN1 2548/4885KMT2A 4045/4885MMP2 1720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.